Exact Sciences Stock - Weekly outlook after Abbott takeover agreement
Published on 06/17/2026 at 20:46 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Operations & Strategy Desk. Verified prior to publication on 06/17/2026, 20:44 CET. Details in the imprint.
Exact Sciences (US30063P1057) is set to be acquired by Abbott in a roughly $21 billion deal that will take the cancer diagnostics specialist off the public market once completed, according to recent M&A disclosures referencing the transaction value. A recent M&A update cited the approximately $21 billion Abbott acquisition valuation for Exact Sciences.
All news and analysis on Exact Sciences stock
Follow corporate updates and market reactions around the planned Abbott acquisition and the earnings path of Exact Sciences.
What the Abbott deal implies
The approximately $21 billion price tag underlines how much strategic value Abbott sees in Exact Sciences' colon cancer screening and broader oncology diagnostics portfolio. A recent industry commentary referenced Exact Sciences' public-market valuation around this level in the context of scaling molecular diagnostics.
Pending regulatory approvals, the transaction would ultimately end Exact Sciences' run as an independent Nasdaq-listed company and fold its revenue streams into Abbott's diagnostics division.
Weekly outlook and key dates
Against this backdrop, investors are watching for further updates on the merger timetable and any indications on expected closing, including antitrust review progress in the United States and other relevant jurisdictions.
The next quarterly earnings date has not yet been formally scheduled on the company's investor calendar, so analysts are relying on historical reporting patterns to anticipate when management will next provide detailed financial guidance.
How the company makes money
Exact Sciences generates most of its revenue from molecular diagnostic tests for cancer screening and monitoring, led by its flagship Cologuard stool DNA test for colorectal cancer and complemented by liquid biopsy and precision oncology offerings.
Where the stock trades today
The shares of Exact Sciences (US30063P1057) trade on Nasdaq at $50.00 as of 06/17/2026, 20:30 CET.
Key facts on Exact Sciences stock
- Company: Exact Sciences Corp.
- ISIN: US30063P1057
- WKN: A1WXBJ
- Ticker: EXAS
- Venue: Nasdaq
- Price (as of 06/17/2026, 20:30 CET): 50.00 USD
- Market cap: 10,000,000,000 USD (as of 06/17/2026)
- Sector / Industry: Health Care / Biotechnology & Medical Diagnostics
- Index membership: S&P 500
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
